Attached files

file filename
EX-99.1 - DAXOR CORPex99-1.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) July 15, 2020

 

Daxor Corporation
(Exact name of registrant as specified in its charter)

 

New York   811-22684   13-2682108
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

350 5th Avenue, New York New York   10118
(Address of principal executive offices)   (Zip Code)

 

212-330-8500
Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock $0.01 par value   DXR   NYSE AMERICAN

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

 

 
 

 

Item 8.01 Other Events

 

On July 15, 2020 Daxor Corporation issued a press release announcing the initiation of first-of-its-kind multicenter BVA-100 study in hospitalized patients with COVID-19. The press release issued is attached to this filing as Exhibit 99.1.

 

Item 9.01 Exhibits

 

(d) Exhibits. The following exhibit is filed with this Current Report on Form 8-K:

 

No. Description

 

99.1 Press release dated July 15, 2020 - Daxor Announces Initiation of First-of-Its-Kind Multicenter BVA-100; Study in Hospitalized Patients With COVID-19

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

  DAXOR CORPORATION
  (Registrant)
   
Date: July 15, 2020 By: /s/ Robert J. Michel
  Name: Robert J. Michel
  Title: Chief Financial Officer